Neil Gunn
Chief Executive Officer at GENETIC SIGNATURES LIMITED
Net worth: - $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Patrizia Paterlini-Bréchot | M | - |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward.
Rarecells USA, Inc.
Rarecells USA, Inc. Packaged SoftwareTechnology Services Rarecells USA, Inc. is a company dedicated to early cancer detection to save lives. The company is based in New York, NY. The company believes that accurate and early cancer detection has the potential to save millions of lives. Rarecells is developing a prostate cancer test and a multi-cancer test for early cancer diagnosis. The company is currently conducting three clinical studies to evaluate the performance of their dedicated iset-based assay. The company was founded in 2011 by Patrizia Paterlini-Bréchot, who has been the CEO since 2011. | 13 years |
Lynn Tetrault | F | 61 | 9 years | |
Karl Pechmann | M | - | 1 years | |
Michael Aicher | M | 64 | 10 years | |
Alessandra Decina | F | - |
Rarecells USA, Inc.
Rarecells USA, Inc. Packaged SoftwareTechnology Services Rarecells USA, Inc. is a company dedicated to early cancer detection to save lives. The company is based in New York, NY. The company believes that accurate and early cancer detection has the potential to save millions of lives. Rarecells is developing a prostate cancer test and a multi-cancer test for early cancer diagnosis. The company is currently conducting three clinical studies to evaluate the performance of their dedicated iset-based assay. The company was founded in 2011 by Patrizia Paterlini-Bréchot, who has been the CEO since 2011.
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | 9 years |
Nicholas Samaras | M | - | 16 years | |
Elizabeth Floegel | F | 48 | 1 years | |
Alicia Olivo | F | 40 | 2 years | |
Jackson Jones | M | - | 7 years | |
Shaun Holt | M | 46 |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | 2 years |
Melody Harris | F | 58 | 2 years | |
Alison Hannah | M | 63 | 9 years | |
Steven Brodie | M | 63 | 9 years | |
Gregory D. Aunan, | - | - | - | |
Stephen Kanovsky | M | 61 | 7 years | |
Jeffrey Sherman | M | 58 | 2 years | |
Anthony Zook | M | 63 | 1 years | |
David Perez | M | 63 | 2 years | |
Michael Kelly | M | 67 | 4 years | |
Chris Smith | M | 61 | 2 years | |
Anthony Radford | M | - | 9 years | |
John Buckels | M | - | 4 years | |
Michael Marks | M | 73 |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | - |
Thierry de Marignac | M | - |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | - |
Albert Bressand | M | - |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | - |
Derek Lyle | M | - | 3 years | |
Warren Stone | M | 51 | 2 years | |
Shashikant Kulkarni | M | 57 | 2 years | |
Hutan Hashemi | M | 45 | 2 years | |
Greg Sparks | M | 56 | - | |
Douglas Millar | M | - | 23 years | |
Gary Passman | M | - | 1 years | |
Neralie Coulston | F | - | 22 years | |
Forrest Holmes Blocker | M | - | - | |
Stephane Chatonsky | M | - | 1 years | |
Isaac Blech | M | 73 |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | - |
Caroline Waldron | F | - | 2 years | |
Christian Brechot | M | 71 |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | - |
Ishan Manaktala | M | - |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | 1 years |
Robin Steele | F | 68 |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
John Melki | M | - | 21 years | |
Ron Chiarello | M | - |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | 8 years |
Peter Manley | M | - | 5 years | |
Rachel Stahler | F | 48 | 3 years | |
Anthony Rule | M | - | 5 years | |
Pooja Goel | F | - |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | 2 years |
Vishal Sikri | M | 48 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 31 | 65.96% |
Australia | 13 | 27.66% |
France | 5 | 10.64% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Neil Gunn
- Personal Network